Characterization of the human T cell response to in vitro CD27 costimulation with varlilumab
Main Authors: | Ramakrishna, Venky, Sundarapandiyan, Karuna, Zhao, Biwei, Bylesjo, Max, Marsh, Henry C., Keler, Tibor |
---|---|
Format: | Online |
Language: | English |
Published: |
BioMed Central
2015
|
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4619281/ |
Similar Items
-
Immune correlates of Varlilumab treated cancer patients are consistent with CD27 costimulatory activity
by: Bullock, Timothy, et al.
Published: (2014) -
The mechanism of anti-tumor immunity induced by varlilumab, a CD27 agonist mAb, is model dependent
by: He, Li-Zhen, et al.
Published: (2015) -
Targeting human CD27 with an agonist antibody stimulates T-cell activation and antitumor immunity
by: Thomas, Lawrence J, et al.
Published: (2014) -
Combination therapies augment the anti-tumor activity of agonist CD27 mAb in human CD27 transgenic mouse models
by: He, Li-Zhen, et al.
Published: (2013) -
Influence of antigen dose and costimulation on the primary response of CD8+ T cells in vitro
Published: (1996)